Literature DB >> 29164269

[Postoperative radiation therapy for prostate cancer : Still no genomic risk profiling for clinical routine].

Tobias Finazzi1, Frank Zimmermann2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29164269     DOI： 10.1007/s00066-017-1232-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

Authors:  Robert B Den; Kasra Yousefi; Edouard J Trabulsi; Firas Abdollah; Voleak Choeurng; Felix Y Feng; Adam P Dicker; Costas D Lallas; Leonard G Gomella; Elai Davicioni; R Jeffrey Karnes
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Bertrand Tombal; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Marc Colombel; Cees van de Beek; Paul Verhagen; Alphonsus van den Bergh; Cora Sternberg; Thomas Gasser; Geertjan van Tienhoven; Pierre Scalliet; Karin Haustermans; Laurence Collette
Journal:  Lancet       Date:  2012-10-19       Impact factor: 79.321

3.  Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.

Authors:  Bradley J Stish; Thomas M Pisansky; William S Harmsen; Brian J Davis; Katherine S Tzou; Richard Choo; Steven J Buskirk
Journal:  J Clin Oncol       Date:  2016-11-10       Impact factor: 44.544

4.  Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base.

Authors:  Helmneh M Sineshaw; Phillip J Gray; Jason A Efstathiou; Ahmedin Jemal
Journal:  Eur Urol       Date:  2015-04-18       Impact factor: 20.096

5.  Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.

Authors:  Deepansh Dalela; María Santiago-Jiménez; Kasra Yousefi; R Jeffrey Karnes; Ashley E Ross; Robert B Den; Stephen J Freedland; Edward M Schaeffer; Adam P Dicker; Mani Menon; Alberto Briganti; Elai Davicioni; Firas Abdollah
Journal:  J Clin Oncol       Date:  2017-03-28       Impact factor: 44.544

Review 6.  Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

Authors:  Daniel E Spratt; Kasra Yousefi; Samineh Deheshi; Ashley E Ross; Robert B Den; Edward M Schaeffer; Bruce J Trock; Jingbin Zhang; Andrew G Glass; Adam P Dicker; Firas Abdollah; Shuang G Zhao; Lucia L C Lam; Marguerite du Plessis; Voleak Choeurng; Zaid Haddad; Christine Buerki; Elai Davicioni; Sheila Weinmann; Stephen J Freedland; Eric A Klein; R Jeffrey Karnes; Felix Y Feng
Journal:  J Clin Oncol       Date:  2017-03-30       Impact factor: 44.544

7.  Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy.

Authors:  Giovanni Lughezzani; Lars Budäus; Hendrik Isbarn; Maxine Sun; Paul Perrotte; Alexander Haese; Felix K Chun; Thorsten Schlomm; Thomas Steuber; Hans Heinzer; Hartwig Huland; Francesco Montorsi; Markus Graefen; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2009-12-10       Impact factor: 20.096

8.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

9.  Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features.

Authors:  Anusha Kalbasi; Samuel Swisher-McClure; Nandita Mitra; Robert Sunderland; Marc C Smaldone; Robert G Uzzo; Justin E Bekelman
Journal:  Cancer       Date:  2014-06-10       Impact factor: 6.860

10.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.